We are live on ! Find out more
CPIX icon

Cumberland Pharmaceuticals
CPIX

45 hedge funds and large institutions have $31.4M invested in Cumberland Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 18 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more capital invested

Capital invested by funds: $30.1M → $31.4M (+$1.28M)

0% more funds holding

Funds holding: 45 → 45 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

67% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 18

Holders
45
Holders Change
–
Holders Change %
0%
% of All Funds
1.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
18
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$337K
2
AIS
AlphaOne Investment Services
Pennsylvania
+$142K
3
Ameriprise
Ameriprise
Minnesota
+$43.9K
4
Renaissance Technologies
Renaissance Technologies
New York
+$35.3K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$20.5K

Top Sellers

Rank Fund Capital Flow
1
KIM
Kestrel Investment Management
California
-$619K
2
LSV Asset Management
LSV Asset Management
Illinois
-$450K
3
AI
Ariel Investments
Illinois
-$271K
4
UCFA
United Capital Financial Advisors
Texas
-$204K
5
BIT
BlackRock Institutional Trust
California
-$142K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
26
Wellington Management Group
Massachusetts
$82K – – –
Bank of New York Mellon
27
Bank of New York Mellon
New York
$81K – – –
DAM
28
Delta Asset Management
Tennessee
$54K – – –
Cambridge Investment Research Advisors
29
Cambridge Investment Research Advisors
Iowa
$49K – – –
Ameriprise
30
Ameriprise
Minnesota
$45K +$43.9K +9,066 New
WA
31
WealthTrust-Arizona
Arizona
$32K – – –
BA
32
BlackRock Advisors
Delaware
$30K – – –
NFA
33
Nationwide Fund Advisors
Ohio
$19K – – –
OC
34
Oakworth Capital
Alabama
$16K – – –
U
35
UBS
Switzerland
$15K -$9.19K -1,900 -38%
Citigroup
36
Citigroup
New York
$14K -$1.45K -300 -10%
BIM
37
BlackRock Investment Management
Delaware
$10K +$1.07K +221 +13%
Creative Planning
38
Creative Planning
Kansas
$8K +$8.23K +1,700 +11,333%
PNC Financial Services Group
39
PNC Financial Services Group
Pennsylvania
$5K – – –
BRWM
40
B. Riley Wealth Management
Tennessee
$4K – – –
Deutsche Bank
41
Deutsche Bank
Germany
$3K -$79K -16,319 -96%
Federated Hermes
42
Federated Hermes
Pennsylvania
$3K +$2.63K +544 New
GSC
43
Ground Swell Capital
South Carolina
$3K +$3.35K +693 New
Manulife (Manufacturers Life Insurance)
44
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3 -$1.72K -356 -35%
KIM
45
Kestrel Investment Management
California
– -$619K -137,500 Closed
LSV Asset Management
46
LSV Asset Management
Illinois
– -$450K -100,200 Closed
State Street
47
State Street
Massachusetts
– -$51K -11,400 Closed
CCMH
48
Cornerstone Capital Management Holdings
New York
– -$3K -800 Closed
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
– -$297 -66 Closed
Bank of America
50
Bank of America
North Carolina
– +$426 +88 New
1
2

CPIX Hedge Fund Activity: Q3 2014 in Review

45 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q3 2014, worth a combined $31.4M — up 4.3% from $30.1M a quarter earlier.

Fund positioning in CPIX was balanced in Q3 2014: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 18 trimmed.

The largest buyer was Millennium Management, adding an estimated $337K. The largest seller was Kestrel Investment Management, exiting entirely with an estimated $619K sold.

  • 45 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q3 2014, unchanged from Q2 2014.
  • Funds reported $31.4M of Cumberland Pharmaceuticals stock for Q3 2014, up 4.3% quarter-over-quarter.
  • 5 funds opened new Cumberland Pharmaceuticals positions in Q3 2014 and 5 closed out, a net change of 0 holders.
  • The largest Cumberland Pharmaceuticals buyer in Q3 2014 was Millennium Management, an estimated $337K added.
  • The largest Cumberland Pharmaceuticals seller in Q3 2014 was Kestrel Investment Management, an estimated $619K sold.

Based on aggregated 13F filings for Q3 2014.